<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   Laboratorios Farmacéuticos ROVI, S.A.
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        462026238
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       159629
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       2
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   Laboratorios Farmacéuticos ROVI manufactures and sells pharmaceuticals in Spain and the rest of Europe. Its best selling prescription drugs include Hibor, (a brand name heparin used to prevent blood clots during surgery), osteoporosis drug Osseor, and angina drug Corlentor. ROVI's handful of OTC products include Autan insect repellant and the Enerzona line of dietary wellness products. Of all ROVI's products, bemiparin is by far its most successful. Bemiparin is a second-generation, low-molecular weight heparin, and is the only medication ROVI markets outside of Europe. The company continues to research new uses for bemiparin and has several other compounds in its research pipeline.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Geographic Reach.flsnp" />
  <p>
   The company has operations in Armenia, Azerbaijan, Bosnia/Herzegovina, Botswana, Brazil, China, Croatia , Ecuador, Egypt, Indonesia, Iran, Israel, Kazakhstan, Kyrgyzstan, Lebanon, Lesotho, Montenegro, Namibia, Pakistan, Peru, Portugal, Qatar, Serbia, South Africa, Sudan, Switzerland, Swaziland, Syria, Taiwan, Tajikistan, Tunisia, the UAE, and Uzbekistan.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Sales and Marketing.flsnp" />
  <p>
   ROVI's entire portfolio of products is marketed in Spain and Portugal. The company sells bemiparin products worldwide through marketing agreements with top pharmaceutical companies in other countries. Bemiparin is sold in more than 50 countries.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Strategy.flsnp" />
  <p>
   In 2013
   <company id="59931">
    Sanofi
   </company>
   agreed to a deal with ROVI through which Sanofi's Rhodogil drug will be marketed by ROVI in Spain.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Company Background.flsnp" />
  <p>
   ROVI was founded in 1946 and went public on the Spanish Stock Exchange in 2007. The company has used the funds from its IPO to help with the construction of a new R&amp;D facility. In 2007 the company acquired Germany's Bertex Pharma, to obtain its pipeline of compounds based on injectable slow-release micro-particles.
  </p>
  <p>
   In 2009 the company licensed Novavax's VLP vaccine technology which it used to create a flu vaccine for the Spanish government. The €60 million ($84 million) program was sponsored by the Spanish Ministry of Health.
  </p>
 <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
